TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on ≥ 1 novel hormonal therapy (NHT)

Open Label ◽

Castration Resistant ◽

Damage Repair

MP87-11 INTERIM ANALYSIS OF AN OPEN LABEL PHASE II STUDY OF ENZALUTAMIDE AND RADIUM RA 233 DICHLORIDE IN SYMPTOMATIC, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS.

The Journal of Urology ◽

10.1016/j.juro.2018.02.2911 ◽

2018 ◽

Vol 199 (4S) ◽

Author(s):

Neal Shore ◽

Paul Schellhammer ◽

Ronald Tutrone ◽

Neil Mariados ◽

Stacey Harrelson

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Interim Analysis ◽

Phase Ii Study ◽

Open Label ◽

Castration Resistant ◽

900 OPEN-LABEL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF PERSONALIZED PEPTIDE VACCINATION (PPV) IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER(CRPC)

The Journal of Urology ◽

10.1016/j.juro.2011.02.2609 ◽

2011 ◽

Vol 185 (4S) ◽

Author(s):

Masanori Noguchi ◽

Fukuko Moriya ◽

Shigetaka Suekane ◽

Kei Matsuoka ◽

Gaku Arai ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Efficacy And Safety ◽

Peptide Vaccination ◽

Open Label ◽

Castration Resistant ◽

Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2020.02.015 ◽

2020 ◽

Vol 18 (5) ◽

pp. 416-422 ◽

Cited By ~ 1

Author(s):

Neal D. Shore ◽

Paul F. Schellhammer ◽

Ronald F. Tutrone ◽

Neil F. Mariados ◽

Stacey S. Harrelson

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Concurrent Administration ◽

Open Label ◽

Castration Resistant ◽

Radium 223 ◽

An open label phase I/randomised, double-blind phase II study in metastatic castration resistant Prostate Cancer of AZD5363 in combination with Docetaxel and prednisolone chemotherapy (ProCAID)

http://isrctn.org/> ◽

10.1186/isrctn69139368 ◽

2014 ◽

Author(s):

Study Coordinator

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Phase Ii ◽

Phase Ii Study ◽

Open Label ◽

Double Blind ◽

Castration Resistant ◽

Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study

Investigational New Drugs ◽

10.1007/s10637-018-0660-3 ◽

2018 ◽

Vol 36 (6) ◽

pp. 1085-1092 ◽

Cited By ~ 2

Author(s):

Pedro C. Barata ◽

Matthew Cooney ◽

Prateek Mendiratta ◽

Allison Tyler ◽

Robert Dreicer ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Open Label ◽

Castration Resistant ◽

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-0394 ◽

2020 ◽

Vol 26 (11) ◽

pp. 2487-2496 ◽

Cited By ~ 45

Author(s):

Wassim Abida ◽

David Campbell ◽

Akash Patnaik ◽

Jeremy D. Shapiro ◽

Brieuc Sautois ◽

...

Keyword(s):

Prostate Cancer ◽

Dna Damage ◽

Phase Ii ◽

Parp Inhibitor ◽

Dna Damage Repair ◽

Repair Gene ◽

Castration Resistant ◽

Damage Repair ◽

Gene Alterations

Faculty Opinions recommendation of A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.3350956.3039058 ◽

2010 ◽

Author(s):

Yoshihiko Hirao ◽

Kiyohide Fujimoto

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant ◽

Transdermal Estradiol ◽

Docetaxel Chemotherapy

Impact of DNA damage repair defects and aggressive variant features on response to carboplatin‐based chemotherapy in metastatic castration‐resistant prostate cancer

International Journal of Cancer ◽

10.1002/ijc.33306 ◽

2020 ◽

Vol 148 (2) ◽

pp. 385-395

Author(s):

Peter H. J. Slootbeek ◽

Marleen L. Duizer ◽

Maarten J. Doelen ◽

Iris S. H. Kloots ◽

Malou C. P. Kuppen ◽

...

Keyword(s):

Prostate Cancer ◽

Dna Damage ◽

Dna Damage Repair ◽

Castration Resistant ◽

Damage Repair ◽

Aggressive Variant

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-12-2605 ◽

2012 ◽

Vol 19 (1) ◽

pp. 215-224 ◽

Cited By ~ 58

Author(s):

Charles J. Ryan ◽

Mark Rosenthal ◽

Siobhan Ng ◽

Joshi Alumkal ◽

Joel Picus ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant ◽

Randomized Phase Ii ◽

Biomarker Analysis

Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-09-1722 ◽

2009 ◽

Vol 15 (22) ◽

pp. 7099-7105 ◽

Cited By ~ 52

Author(s):

Mary-Ellen Taplin ◽

Meredith M. Regan ◽

Yoo-Joung Ko ◽

Glenn J. Bubley ◽

Stephen E. Duggan ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Synthesis Inhibition ◽

Androgen Synthesis ◽

Castration Resistant